에 대한 최신 뉴스 Peakstone Realty Tr (NYSE:PKST) 주식

Peakstone Realty Tr

Peakstone Realty Trust is an internally managed, publicly registered real estate investment trust (REIT) that owns and operates predominately single-tenant industrial and office properties with creditworthy tenants and long-term leases. Peakstone's portfolio consists of newer vintage, and well-located real estate assets in majorly high-growth coastal and sunbelt markets. The company has two reportable segments: Industrial and Office. The Industrial segment consists of industrial outdoor storage properties which have a low building-to-land ratio, or low coverage, maximizing yard space for the display, movement, and storage of materials and equipment. The Office segment includes office, R&D and data center properties.

Peakstone Realty Trust

UBS analyst John Nadel maintains Principal Financial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) with a Neutral and lowers the price target from $93 to $80.

News

Price Target

Analyst Ratings

UBS Maintains Neutral on Principal Financial Group, Lowers Price Target to $80

UBS analyst Pradeep Ramani maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Neutral and lowers the price target from $55 to $40.

UBS Maintains Neutral on ON Semiconductor, Lowers Price Target to $40

WIIM

Wells Fargo shares are trading higher after the company's board authorized a $40 billion stock repurchase program.

UBS analyst Kunal Madhukar maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Neutral and lowers the price target from $34 to $31.

MTCH

UBS Maintains Neutral on Match Group, Lowers Price Target to $31

Correction: Guggenheim analyst Michael Schmidt downgrades SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) from Buy to Neutral and lowers the price target from $77 to $47. (Analyst Firm change from Stephens &amp; Co. to Guggenheim)

Downgrades

SWTX

Correction: Guggenheim Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47 (Firm change from Stephens & Co. to Guggenheim)

BMO Capital analyst Michael Zaremski maintains Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) with a Outperform and raises the price target from $92 to $96.

SIGI

BMO Capital Maintains Outperform on Selective Insurance Gr, Raises Price Target to $96

UBS analyst Taylor McGinnis maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Neutral and lowers the price target from $350 to $310.

MNDY

UBS Maintains Neutral on Monday.Com, Lowers Price Target to $310

BMO Capital analyst Ari Klein maintains SBA Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) with a Market Perform and raises the price target from $230 to $240.

SBAC

BMO Capital Maintains Market Perform on SBA Communications, Raises Price Target to $240

UBS analyst Pradeep Ramani maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and lowers the price target from $70 to $55.

MCHP

UBS Maintains Buy on Microchip Technology, Lowers Price Target to $55

AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) has outperformed the market over the past 20 years by 8.88% on an annualized basis producing an average annual return of 16.92%. Currently, AZZ has a market capitalization of $2.57 billion. 
Buying $1000 In AZZ: If an investor had bought $1000 of AZZ stock 20 years ago, it would be worth $22,594.59 today based on a price of $86.00 for AZZ at the time of writing.
<h3>AZZ's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745937911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

BMO Capital analyst Andrew Strelzik maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Outperform and raises the price target from $515 to $540.

BMO Capital Maintains Outperform on Domino's Pizza, Raises Price Target to $540

UBS analyst Danielle Antalffy maintains InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) with a Neutral and lowers the price target from $19 to $16.25.

INMD

UBS Maintains Neutral on InMode, Lowers Price Target to $16.25

BMO Capital analyst James Thalacker maintains CMS Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>) with a Outperform and raises the price target from $77 to $79.

BMO Capital Maintains Outperform on CMS Energy, Raises Price Target to $79

UBS analyst Timothy Arcuri maintains GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral and lowers the price target from $45 to $37.

UBS Maintains Neutral on GLOBALFOUNDRIES, Lowers Price Target to $37

Piper Sandler analyst James Fish maintains F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) with a Neutral and raises the price target from $262 to $269.

FFIV

Piper Sandler Maintains Neutral on F5, Raises Price Target to $269

UBS analyst Timothy Arcuri maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Neutral and lowers the price target from $115 to $90.

ENTG

UBS Maintains Neutral on Entegris, Lowers Price Target to $90

Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) with a Overweight and raises the price target from $90 to $105.

Reiteration

TMDX

Piper Sandler Reiterates Overweight on TransMedics Group, Raises Price Target to $105

UBS analyst Timothy Arcuri maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Buy and lowers the price target from $215 to $165.

UBS Maintains Buy on ARM Holdings, Lowers Price Target to $165

Piper Sandler analyst Matthew Clark maintains Preferred Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFBC#NASDAQ">PFBC</a>) with a Overweight and lowers the price target from $108 to $96.

Comments

Peakstone Realty Tr

뉴스

에 대한 최신 뉴스 Peakstone Realty Tr (NYSE:PKST) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌